Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Rajabu Hussein Mnkugwe"'
Autor:
Adam M. Fimbo, Rajabu Hussein Mnkugwe, Eulambius Mathias Mlugu, Peter P. Kunambi, Alpha Malishee, Omary M.S. Minzi, Appolinary A. R. Kamuhabwa, Eleni Aklillu
Publikováno v:
Infectious Diseases of Poverty, Vol 13, Iss 1, Pp 1-13 (2024)
Abstract Background Preventive chemotherapy with ivermectin and albendazole (IA) in mass drug administration (MDA) programs for all at-risk populations is the core public health intervention to eliminate lymphatic filariasis (LF). Achieving this goal
Externí odkaz:
https://doaj.org/article/3b57bc9cffb540c1917ff7f74f74019a
Autor:
Tigist Dires Gebreyesus, Eyasu Makonnen, Nigus Fikrie Telele, Abbie Barry, Rajabu Hussein Mnkugwe, Heran Gerba, Marja-Liisa Dahl, Eleni Aklillu
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract Metabolism of praziquantel (PZQ), a racemic mixture and the only drug approved to treat S. mansoni infection, is mediated by genetically polymorphic enzymes. Periodic school-based mass drug administration (MDA) with PZQ is the core intervent
Externí odkaz:
https://doaj.org/article/2bafea5de4f74380983c947626a0106c
Autor:
Adam Fimbo, Yonah H. Mwalwisi, Kissa Mwamwitwa, Damas Matiko, Elirehema Mfinanga, Johnson Lyimo, Amon Sabasaba, Seth Missago, Elias Bukundi, Goodluck Gotora, Dorice Respick, Alex Nkayamba, Emmanuel Masunga, Rajabu Hussein Mnkugwe, Peter P. Kunambi, Castory Munishi, Christine Chiedza Musanhu, Omary M. S. Minzi, Eulambius M. Mlugu
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Tanzania adopted a Dolutegravir (DTG)-based regimen as first-line treatment in 2019 following the World Health Organization recommendation. Data on the DTG safety profile from sub-Saharan Africa including Tanzania are limited. We investigate
Externí odkaz:
https://doaj.org/article/ea7b4164469246fb93a1c4f5c70cff76
Autor:
Adam M. Fimbo, Eulambius M. Mlugu, Eliford Ngaimisi Kitabi, Gerald S. Kulwa, Mohammed A. Iwodyah, Rajabu Hussein Mnkugwe, Peter P. Kunambi, Alpha Malishee, Appolinary A. R. Kamuhabwa, Omary M. Minzi, Eleni Aklillu
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 12, Pp 1884-1896 (2023)
Abstract Ivermectin (IVM) is a drug of choice used with albendazole for mass drug administration (MDA) to halt transmission of lymphatic filariasis. We investigated IVM pharmacokinetic (PK) variability for its dose optimization during MDA. PK samples
Externí odkaz:
https://doaj.org/article/8eb56a80061b4c679a9f5a5480a7eaf8
Autor:
Abbie Barry, Joseph Kabatende, Nigus Fikrie Telele, Rajabu Hussein Mnkugwe, Michael Mugisha, Lazare Ntirenganya, Emile Bienvenu, Eleni Aklillu
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-11 (2023)
Abstract School-based mass drug administration (MDA) of Praziquantel (PZQ) is the global intervention strategy for elimination of schistosomiasis. Genetic variations in drug metabolizing enzymes and transporter proteins influences drug exposure and t
Externí odkaz:
https://doaj.org/article/e69e9dcd92d2477bbc7fd316282bcbf6
Autor:
Rajabu Hussein Mnkugwe, Eliford Ngaimisi Kitabi, Safari Kinung’hi, Appolinary A. R. Kamuhabwa, Omary Mashiku Minzi, Eleni Aklillu
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
Abstract Praziquantel pharmacokinetics studies in schistosomiasis infected children are scarce partly due to the challenges/complexity of intensive blood sampling in the target population. This study was aimed to investigate the optimal single sampli
Externí odkaz:
https://doaj.org/article/94f4d46daa4948c4ba9c381e4f310157
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Studies on pharmacogenetics of praziquantel (PZQ) and its relevance on plasma drug concentrations and schistosomiasis treatment outcomes are lacking. We investigated the effect of pharmacogenetics variations of PZQ on plasma drug levels and schistoso
Externí odkaz:
https://doaj.org/article/d7809d294e4648ada83db3499c59de4f
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 14, Iss 9, p e0008619 (2020)
BackgroundDespite the reported success in reducing morbidity, praziquantel alone is insufficient for the control and elimination of schistosomiasis, partly due to its poor efficacy against the juvenile worms. Artemisinin derivatives are effective aga
Externí odkaz:
https://doaj.org/article/8cf7869d229e4c61a3c26ffe2dd52890
Autor:
Rajabu Hussein Mnkugwe, Omary S Minzi, Safari M Kinung'hi, Appolinary A Kamuhabwa, Eleni Aklillu
Publikováno v:
PLoS ONE, Vol 15, Iss 2, p e0228770 (2020)
BACKGROUND:Schistosomiasis is a neglected tropical disease that continues to cause morbidity and mortality in Sub Saharan Africa. Due to its endemicity, co-infection with malaria is common. The diseases cause anaemia and impaired nutritional status a
Externí odkaz:
https://doaj.org/article/fa3285cfa6624f8d941d324fda8eea6d
Autor:
Omary Mashiku Minzi, Rajabu Hussein Mnkugwe, Eliford Ngaimisi, Safari Kinung’hi, Anna Hansson, Anton Pohanka, Appolinary Kamuhabwa, Eleni Aklillu
Publikováno v:
Pharmaceuticals, Vol 14, Iss 5, p 400 (2021)
Praziquantel (PZQ) and dihydroartemisinin-piperaquine (DHP) combination recently showed superior effectiveness than PZQ alone to treat intestinal schistosomiasis. In this follow-up study, we investigated the effect of DHP co-administration on the pha
Externí odkaz:
https://doaj.org/article/993ad5526c61414883f74673dd0707fe